In8Bio (INAB) Share-based Compensation (2020 - 2026)
In8Bio (INAB) posted Share-based Compensation of $400000.0 for Q1 2026, down 43.74% sequentially from $711000.0 in Q4 2025, and down 51.87% YoY from $831000.0 in Q1 2025.
In8Bio (INAB) Share-based Compensation (2020 - 2026) Analysis & Trends
In8Bio has reported Share-based Compensation for 7 years, with the latest figure at $400000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 51.87% year-over-year to $400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $400000.0 (up 2.3% YoY) and the FY2025 annual result came in at $3.2 million, down 25.84% from the prior year.
- Share-based Compensation fell to $400000.0 in Q1 2026 per INAB's latest filing, from $711000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.8 million in Q4 2023 and troughed at -$3.4 million in Q4 2024.
- A 5-year average of $1.1 million and a median of $897000.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 315.84% in 2023, then tumbled 188.03% in 2024.
- Over 5 years, Share-based Compensation stood at $922000.0 in 2022, then surged by 315.84% to $3.8 million in 2023, then sank by 188.03% to -$3.4 million in 2024, then surged by 121.07% to $711000.0 in 2025, then sank by 43.74% to $400000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $400000.0, $711000.0, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | 352,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 352,000.00 |
| Jun 30, 2026 | 352,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | 711,000.00 |
| Dec 31, 2025 | 711,000.00 |
| Sep 30, 2025 | 2.60 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 831,000.00 |
| Mar 31, 2025 | 831,000.00 |
| Dec 31, 2024 | -3.38 Mn |
| Dec 31, 2024 | -3.38 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Mar 31, 2024 | 714,000.00 |
| Mar 31, 2024 | 714,000.00 |